17:57 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

BioCardia's CardiAMP non-significantly improves 6MWD in roll-in cohort of Phase III for heart failure

BioCardia Inc. (OTCQX:BCDA) reported data from the 10-patient roll-in cohort of the Phase III CardiAMP Heart Failure trial to treat heart failure following a heart attack showing that CardiAMP non-significantly improved mean 6-minute walk distance...
07:00 , Oct 20, 2014 |  BC Week In Review  |  Company News

BioCardia, CellProThera deal

Early next year, CellProThera and BioCardia will conduct the Phase I/IIb EXCELLENT trial evaluating CellProThera's Protheracytes CD34+ cells delivered by BioCardia's Helix Transendocardial delivery system. The trial will enroll 44 patients in the U.K. and...
07:00 , May 26, 2014 |  BC Week In Review  |  Clinical News

JVS-100: Interim Phase II data

Juventas reported interim 4-month data from the double-blind, U.S. Phase II STOP-HF trial in 93 patients with symptomatic ischemic cardiomyopathy showing that a single injection of 30 mg JVS-100 non-significantly improved left ventricular end systolic...
08:00 , Dec 16, 2013 |  BC Week In Review  |  Clinical News

Helical Infusion System: Phase I/II data

The double-blind, placebo-controlled, U.S. Phase I/II TAC-HFT trial in 65 patients with chronic ischemic left ventricular dysfunction due to ischemic cardiomyopathy showed that 200 million autologous culture-expanded mesenchymal stem cells (MSCs) or minimally-processed whole bone...
08:00 , Nov 4, 2013 |  BC Week In Review  |  Clinical News

JVS-100: Completed Phase II enrollment

Juventas completed enrollment of 93 patients with ischemic heart failure in the double-blind, placebo-controlled, U.S. Phase II STOP-HF trial evaluating single doses of 15 and 30 mg JVS-100 delivered via endomyocardial injection with the Helical...
07:00 , Aug 27, 2012 |  BC Week In Review  |  Clinical News

JVS-100: Phase II started

Juventas began the double-blind, placebo-controlled U.S. Phase II STOP-HF trial to evaluate single doses of 15 and 30 mg JVS-100 delivered via endomyocardial injection with the Helical Infusion System from BioCardia Inc. (San Carlos, Calif.)...
07:00 , Mar 26, 2012 |  BC Week In Review  |  Clinical News

JVS-100: Phase II start

Next quarter, Juventas will begin a Phase II trial to evaluate JVS-100 delivered with the Helical Infusion System from BioCardia Inc. (San Carlos, Calif.) in adults. BioCardia's Helical Infusion System is a steerable 2 catheter...